3 completed, 2 unknown, 1 recruiting, 1 withdrawn. 2 Not applicable, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 1, Unknown 1 |
| Phase 1 | 1 | Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Eosinophilic Fasciitis: new trials by email Literature Review of Eosinophilic Fasciitis trials Research Report on Eosinophilic Fasciitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| EFESO: Study on Juvenile Onset Eosinophilic Fasciitis Eosinophilic Fasciitis | Recruiting | Meyer Children's Hospital IRCCS | 20 | 2025-05-15 | 2026-03-11 | |
| High-Intensity Laser Therapy for Eosinophilic Fasciitis High-Intensity Laser Therapy - Eosinophilic Fasciitis | Not applicable | Unknown | Ahram Canadian University | 1 | 2023-06-18 | 2023-06-23 |
| Mepolizumab for Eosinophilic Fasciitis Mepolizumab - Eosinophilic Fasciitis | Phase 1 | Withdrawn | Mayo Clinic | 2023-02-01 | 2024-11-20 | |
| The Influence of Extracorporeal Photopheresis on Skin Sclerosis Scleroderma, Systemic, Graft Vs Host Disease | Completed | Charite University, Berlin, Germany | 6 | 2021-02-12 | 2022-11-17 | |
| Shulman Fasciitis Prevalence Study in Alsace Shulman Fasciitis | Unknown | University Hospital, Strasbourg, France | 30 | 2016-07-01 | 2017-04-27 | |
| A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy Rituximab - Debilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis) | Phase 2 | Completed | University Hospital, Ghent | 3 | 2009-06-01 | 2021-07-13 |
| Treatment With High Dose Methotrexate in Patients With Eosinophilic Fasciitis methotrexate - Fasciitis | Not applicable | Completed | Radboud University Medical Center | 6 | 2006-10-01 | 2011-08-11 |
Fasciitis (2) · Scleroderma, Localized (2) · Graft vs Host Disease (1) · Juvenile-onset scleroderma (1) · Scleroderma, Systemic (1)
Connective Tissue Diseases (2) · Musculoskeletal Diseases (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Immune System Diseases (1)
Methotrexate (1) · Rituximab (1) · mepolizumab (1)
Ahram Canadian University (1) · Charite University, Berlin, Germany (1) · Mayo Clinic (1) · Meyer Children's Hospital IRCCS (1) · Radboud University Medical Center (1) · University Hospital, Ghent (1) · University Hospital, Strasbourg, France (1)
Germany (2) · Belgium (1) · Croatia (1) · Egypt (1) · France (1) · Israel (1) · Italy (1) · Netherlands (1) · Romania (1) · Slovenia (1) · Spain (1) · Sweden (1) · Turkey (Türkiye) (1) · United Kingdom (1) · United States (1)
Amal Fawzy, Ph.d (1) · Filip De Keyser, MD, PhD (1) · H. Knaapen, MD (1) · Jason C Sluzevich, M.D. (1) · Ulrike Blume-Peytavi, Prof. MD (1)